Urology
Volume 70, Issue 6, Supplement 1 , Pages S36-S41 , December 2007

Chemotherapy Followed by Syngeneic Dendritic Cell Injection in the Mouse: Findings and Implications for Human Treatment

  • William A. Cavanagh

      Affiliations

    • Corresponding Author InformationReprint requests: William A. Cavanagh, BS, The Haakon Ragde Foundation for Advanced Cancer Studies, 1100 Dexter Avenue North, Seattle, Washington 98109.
    • Mr. Cavanagh and Dr. Tjoa are named [patent] inventors for a treatment concept [the product] mentioned in this article.
    • ,
  • Benjamin A. Tjoa

      Affiliations

    • Mr. Cavanagh and Dr. Tjoa are named [patent] inventors for a treatment concept [the product] mentioned in this article.
    • ,
  • Haakon Ragde

      Affiliations

    • Dr. Ragde has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.

References 

  1. Slingluff CL, Speiser DE. Progress and controversies in developing cancer vaccines. J Transl Med. 2005;3:18–27
  2. Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3–15
  3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol. 2005;23:1147–1157
  4. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 2003;21:873–886
  5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  6. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894–3903
  7. Tjoa BA, Lodge PA, Salgaller ML, et al. Dendritic cell–based immunotherapy for prostate cancer. Cancer. 1999;49:117–128
  8. Ragde H, Cavanagh W, Tjoa B. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol. 2004;172:2532–2538
  9. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate–pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8:1021–1032
  10. Santin AD, Bellone S, Ravaggi A, et al. Induction of ovarian tumor–specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000;96:422–430
  11. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. [see comment] J Clin Invest. 2002;109:409–417
  12. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow–derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001;61:7530–7535
  13. Shin JY, Lee SK, Kang CD, et al. Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model. Histol Histopathol. 2003;18:435–447
  14. Choi GS, Lee MH, Kim SK, et al. Combined treatment of an intratumoral injection of dendritic cells and systemic chemotherapy (Paclitaxel) for murine fibrosarcoma. Yonsei Med J. 2005;46:835–842
  15. Tanaka F, Yamaguchi H, Ohta M, et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer. 2002;101:265–269
  16. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 2005;65:5958–5964
  17. Yu B, Kusmartsev S, Cheng F, et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res. 2003;9:285–294
  18. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 2003;63:8466–8475
  19. Machlenkin A, Goldberger O, Tirosh B, et al. Combined dendritic cell cryotherapy of tumor induces sytemic antimetastatic immunity. Clin Cancer Res. 2005;11:4955–4961
  20. Udagawa M, Kudo-Saito C, Hasegawa G, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and bacillus Calmette-Guérin cell wall skeleton stimulation. Clin Cancer Res. 2006;12:7465–7475
  21. Morse MA, Chui S, Hobeika A, et al. Recent developments in therapeutic cancer vaccines. Nature Clin Pract Oncol. 2005;2:108–113
  22. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev Cancer. 2005;5:263–274
  23. Feijoo E, Alfaro C, Mazzolini G, et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer. 2005;116:275–281
  24. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–562
  25. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245–1253
  26. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci U S A. 2005;102:419–424
  27. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006;177:896–904
  28. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115–123
  29. Quezada SA, Peggs KS, Curran MA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935–1945
  30. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623–3633
  31. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. [see comment] Nature Med. 2004;10:942–949
  32. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother. 1998;47:1–12
  33. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868
  34. Ghiringhelli F, Menard C, Puig P, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end-stage cancer patients. Cancer Immunol Immunother. 2007;56:641–648
  35. den Brok MH, Sutmuller RP, Nierkens S, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95:896–905

PII: S0090-4295(07)01803-1

doi: 10.1016/j.urology.2007.06.1127

Urology
Volume 70, Issue 6, Supplement 1 , Pages S36-S41 , December 2007

Article Tools